You wrote:
Thanks, nice post. I agree with most of your comments, but oral Brilacidin has been shown numerous times to not be absorbed systemically.
First of all, the IV portion of Bril is systematically absorbed with 100% bioavailability in plasma protein of the blood! However, you are right about the IBD/UC po drug intentionally made by Oralogic to treat IBD/UC and to have very limited systemic absorption, as such it was intended to go target the colon. But at this point, the po version for IBD/UC will not be repurposed, so that leaves us with the IV option only for the interim period. The possibility is there to come up with po form for prophylaxis to prevent and even address mild cv19 occurrence. But that's another story just as your inhaler idea as well. However, repurposing the po version may give us another opportunity in the GI portion since some patients are experiencing abnormalities with thickening of the bowel wall and ischemia. SARsCoV2 viral replication as the culprit in the intestine as the explanatory cause.
I'm not sure why you brought this up?
"I am not aware of any reports linking the GI disorder with later severe pulmonary failure."
SARsCOV2 maybe RNA based compared to influenza but they do not share the same homology from each other in terms of structure. SARsCOv is 83% and MERsCoV is 56% and a big drop off from the rest of other flu pandemics such as H1N1, etc., etc. But my point was, if the Juggernaut (character) Bril can address CV19, then it's more likely to be the key or the backbone of future therapeutic for pandemic flu to shorten the duration or episode that leads to their pathogenesis.
Do you think the LEO doesn't read this site? Obviously, I did mention Remdesivir as a potential placebo to send shock waves, but it's a coincidence that the drug was mentioned too. That drug has serious renal and liver concerns with cv19 patients and a much higher death rate than what was originally disclosed that came out of China.
We have a great drug here and I'm very confident for damn good success in the human lungs and other results we are waiting. Binding should be much faster with h l epithelial cells. Sp should easily fill the 1.84 gap. But no doubt with any funding we will hit $3. Let's hope we get multiple grants and big funding from the government so we can get to $4+ after the trial is initiated. GLTA! Black Diamond in here.
TAGB
